Evaluation of the Anti-Inflammatory Effects of Glucocorticoids
Abstract
The purpose of this article is to study the pros and cons of glucocorticoids in anti-inflammatory effects and to evaluate them. Because inflammation can play a positive role in removing pathogens and recovering the body on the one hand, it can also bring about adverse reactions such as redness, swelling, heat, and pain. Therefore, understanding the pros and cons of glucocorticoids in anti-inflammatory effects has the guiding significance in the clinical drug use.
Based on the complexity of the clinical effects of glucocorticoids on the patient’s body, this article first analyzes the specific symptoms of inflammation, which are mainly manifested as redness, swelling, heat, pain, and dysfunction, and then analyzes the mechanism of inflammation, which is mainly due to body fluid leakage and the role of cytokines.
Then, based on the symptoms and mechanism of inflammatory episodes, the inflammatory episodes are divided into fatal and non-fatal attacks, and three dosage regimens are designed. On this basis, the three dosage regimens were evaluated in the treatment of fatal and non-fatal seizures from four indicators of safety, effectiveness, stability, and uniformity, and the following evaluation results were obtained.
In the treatment of fatal diseases, the evaluation weight of the A program is 0.587384, the evaluation weight of the B program is 0.202727, and the evaluation weight of the C program is 0.209809. In the treatment of non-fatal diseases, the evaluation weight of the A plan is 0.5462, the B plan is 0.261573, and the C plan is 0.192148.
Analyze the three programs in the fatal disease situation and the non-fatal disease situation respectively, and draw the experimental conclusion that the comprehensive evaluation result of the A program is better than the B and C programs whether it is to treat fatal or non-fatal diseases. In the treatment of fatal diseases, the C program is slightly better than the B program, and in the treatment of non-fatal diseases, the B program is better than the C program.
References
[2] Yang Baofeng. Pharmacology [M]. People's Medical Publishing House, 2020-1.
[3] Li Gandi. Pathology [M]. People's Medical Publishing House, 2001-9.
[4] Jin Boquan. Medical Immunology [M]. People's Medical Publishing House, 2008-6 (75-79).
[5] Zhang Le. Improvement of Analytic Hierarchy Process and its application in weight determination[J]. China Health Statistics, 2016-02-25.
[6] Yang Jia, Deng Danqi. The pros and cons of corticosteroid shock therapy for SLE[J]. Dermatology and Venereal Diseases, 2013-12.
[7] Li Juan. Master of Applied Research of Analytic Hierarchy Process in the Selection of Quality Evaluation Indexes for Drug Clinical Trials[D]. Nanchang University, 2017-06-10.
[8] Zhang Yuanyuan. Based on the Delphi method and analytic hierarchy process to construct the risk assessment scale of medical adhesive-related skin damage in hospitalized children[J]. Journal of Nurses Training, 2021-07-10.
[9] Zhu Liqin. Research on drug safety evaluation and control based on clinical pharmacists [D]Tianjin University, 2011-05-01.
[10] Li Xingang. Clinical study of glucocorticoids in the treatment of severe patients with new coronavirus pneumonia[J]. Journal of Capital Medical University, 2020-05-28.
Copyright (c) 2021 Jichen Li
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
